P. Hellemans

发表

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

J. Murphy, J. Snoeys, R. de Vries, 2015, Pharmacology research & perspectives.

COMMENT ON: TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST CARCINOMA. AUTHORS' REPLY

K. Chew, B. Ljung, S. Fox, 1995 .

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

J. Camm, R. Plummer, R. Cowan, 2013, Clinical Cancer Research.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

F. Saad, R. de Wit, W. Edenfield, 2018, Cancer Chemotherapy and Pharmacology.

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome

M. Weichenthal, R. Cowan, M. Beylot-Barry, 2016, The British journal of dermatology.

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

D. Ouellet, J. Jiao, J. de Jong, 2020, Pharmacology research & perspectives.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

J. Carles, I. Durán, J. Jiao, 2020, Clinical Pharmacokinetics.

Fetal fibronectin detection for prediction of preterm birth in low risk women

P. Hellemans, J. Gerris, P. Verdonk, 1995, British journal of obstetrics and gynaecology.

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

P. Moreau, X. Leleu, C. Touzeau, 2016, Leukemia & lymphoma.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study

D. Ouellet, I. Poggesi, M. De Meulder, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma.

T. Plesner, H. Nahi, A. Oriol, 2019, Blood.

A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours

M. Janicot, W. Aherne, J. Bono, 2007 .

University of Southern Denmark Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma

Clemens, Donk, T. Plesner, 2021 .

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

T. Plesner, H. Nahi, A. Oriol, 2020, Haematologica.

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

R. Verona, V. Moreno, E. Calvo, 2022, Investigational New Drugs.

Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma.

E. van Marck, P. Vermeulen, L. Dirix, 1995, Journal of the National Cancer Institute.

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

T. Plesner, H. Nahi, A. Oriol, 2017 .

Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility.

P. Hellemans, J. Gerris, F. Comhaire, 1991 .

Serum hCG decline following salpingotomy or salpingectomy for extrauterine pregnancy.

P. Hellemans, J. Gerris, P. Verdonk, 1994, European journal of obstetrics, gynecology, and reproductive biology.

Placebo‐controlled trial of high‐dose Mesterolone treatment of idiopathic male infertility

P. Hellemans, J. Gerris, F. Comhaire, 1992, Fertility and sterility.

Preliminary results with the use of the ROM-check immunoassay in the early detection of rupture of the amniotic membranes.

P. Hellemans, J. Gerris, M. Baekelandt, 1992, European journal of obstetrics, gynecology, and reproductive biology.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

M. D. de Jonge, H. Arkenau, J. D. de Bono, 2015, Clinical Cancer Research.

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

J. Byrd, S. O'brien, J. Murphy, 2015, Cancer Chemotherapy and Pharmacology.

Prognostic value of bcl-2 expression in invasive breast cancer.

E. van Marck, P. V. van Dam, J. Weyler, 1995, British Journal of Cancer.

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. de Jong, 2017, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

F. Saad, E. Posadas, M. D. de Jonge, 2020, Clinical Cancer Research.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

J. Friedberg, I. Flinn, Y. Oki, 2014, The Lancet. Oncology.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Juthamas Sukbuntherng, Jan Snoeys, L. D. De Zwart, 2016, British journal of clinical pharmacology.

The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure

D. Ouellet, J. Jiao, J. Sukbuntherng, 2018, Cancer Chemotherapy and Pharmacology.

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

E. van Marck, A. V. van Oosterom, P. Hellemans, 1995, Journal of clinical pathology.

A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.

V. Moreno, E. Calvo, P. Hellemans, 2019, Journal of Clinical Oncology.

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

T. Plesner, H. Nahi, A. Oriol, 2023, Leukemia & lymphoma.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

William Smith, T. Marbury, E. Lawitz, 2017, Leukemia & lymphoma.

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

T. Plesner, H. Nahi, A. Oriol, 2016 .

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. Sukbuntherng, 2017, Cancer Chemotherapy and Pharmacology.

Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

F. Saad, E. Posadas, T. Friedlander, 2017 .

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

J. Verweij, H. Burger, M. D. de Jonge, 2010, British Journal of Cancer.

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

X. Leleu, C. Touzeau, T. Facon, 2013 .

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

J. Jiao, P. Hellemans, N. Haddish-Berhane, 2024, Clinical pharmacokinetics.

Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma.

P. Moreau, X. Leleu, C. Touzeau, 2013 .